Ligand Pharmaceuticals | LGND - Assets


Ligand Pharmaceuticals reported $1.48B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Agenus USD 233.89M 48.67M Sep/2025
Amgen USD 90.59B 445M Dec/2025
Anika Therapeutics USD 189.44M 1.76M Sep/2025
Arrowhead Research USD 1.6B 218.89M Dec/2025
Baxter International USD 20.06B 1.01B Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Enviri Corporation USD 2.79B 23.29M Sep/2025
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Glaxosmithkline GBP 82.45B 23.19B Sep/2025
Heron Therapeutics USD 248.95M 16.86M Sep/2025
Insmed USD 2.26B 96.18M Dec/2025
Intrexon USD 73.16M 77.88M Jun/2024
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Karyopharm Therapeutics USD 96.23M 8.65M Sep/2025
Ligand Pharmaceuticals USD 1.48B 528.17M Sep/2025
MacroGenics USD 270.76M 25.34M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Pacira USD 1.3B 239.68M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Veracyte USD 1.37B 23.68M Sep/2025